• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ISOPROTERENOL Drug Record

  • Summary
  • Interactions
  • Claims
  • ISOPROTERENOL chembl:CHEMBL434 Approved

    Alternate Names:

    ISOPROTERENOL
    NSC-9975
    ISOPROTERENOL DL-FORM
    NSC-33791
    ISOPRENALINE
    A-21
    3,4-DIHYDROXY-ALPHA-[(ISOPROPYLAMINO)METHYL]BENZYL ALCOHOL
    (+-)-ISOPRENALINE
    1-(3,4-DIHYDROXYPHENYL)-2-ISOPROPYLAMINOETHANOL
    N-ISOPROPYL-BETA-DIHYDROXYPHENYL-BETA-HYDROXYETHYLAMINE
    N-ISOPROPYLNORADRENALINE
    Α-(ISOPROPYLAMINOMETHYL)PROTOCATECHUYL ALCOHOL
    (±)-ISOPROTERENOL
    1-(3,4-DIHYDROXYPHENYL)-2-(ISOPROPYLAMINO)ETHANOL
    ISOPRENALINUM
    (±)-ISOPRENALINE
    ISOPROPYL NORADRENALINE
    N-ISOPROPYL-Β-DIHYDROXYPHENYL-Β-HYDROXYETHYLAMINE
    ISOPRENALINA
    N-ISOPROPYLNOREPINEPHRINE
    (+-)-ISOPROTERENOL
    ALPHA-(ISOPROPYLAMINOMETHYL)PROTOCATECHUYL ALCOHOL
    chemidplus:7683-59-2
    pubchem.compound:3779
    chembl:CHEMBL434
    drugbank:01064

    Drug Info:

    Drug Class bronchodilator agents
    Drug Class cardiotonic agents
    Year of Approval approved before 1982
    FDA Approval Approved before 1982
    Drug Class small molecule
    Drug Indications Cardiotonic Agents
    Drug Indications Bronchodilator Agents
    (4 More Sources)

    Publications:

    Levi et al., 1993, Human immunodeficiency virus coat protein gp120 inhibits the beta-adrenergic regulation of astroglial and microglial functions., Proc. Natl. Acad. Sci. U.S.A.
    Ahlquist, 1976, Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor., Am. Heart J.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Jurgens et al., 2005, Beta1 adrenergic receptor-mediated enhancement of hippocampal CA3 network activity., J. Pharmacol. Exp. Ther.
    Kobayashi et al., 2005, Beta-arrestin2 enhances beta2-adrenergic receptor-mediated nuclear translocation of ERK., Cell. Signal.
    Sato et al., 2004, Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/Ca(2+)-exchanger., J. Mol. Cell. Cardiol.
    McCrink KA et al., 2016, β<sub>1</sub>-adrenoceptor Arg389Gly polymorphism confers differential β-arrestin-binding tropism in cardiac myocytes., Pharmacogenomics
    Dishy V et al., 2001, The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization., N Engl J Med
    Angers et al., 2001, Biochemical and biophysical demonstration of GPCR oligomerization in mammalian cells., Life Sci.
    Ding et al., 2000, Modulation of porcine adipocyte beta-adrenergic receptors by a beta-adrenergic agonist., J. Anim. Sci.
    Skoumbourdis AP et al., 2009, Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors., Bioorg Med Chem Lett
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    Jones et al., 2003, Enhanced beta2-adrenergic receptor (beta2AR) signaling by adeno-associated viral (AAV)-mediated gene transfer., BMC Pharmacol.
    Odley et al., 2004, Regulation of cardiac contractility by Rab4-modulated beta2-adrenergic receptor recycling., Proc. Natl. Acad. Sci. U.S.A.
    Uezono et al., 2004, Involvement of G protein betagamma-subunits in diverse signaling induced by G(i/o)-coupled receptors: study using the Xenopus oocyte expression system., Am. J. Physiol., Cell Physiol.
    Teixeira et al., 2004, Atypical beta-adrenoceptor subtypes mediate relaxations of rabbit corpus cavernosum., J. Pharmacol. Exp. Ther.
    Abraham et al., 2003, Pharmacological and biochemical characterization of the beta-adrenergic signal transduction pathway in different segments of the respiratory tract., Biochem. Pharmacol.
    Lemmens et al., 2004, Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase., Circulation
    Morimoto et al., 2001, Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells., J. Lipid Res.
    Borger et al., 1998, Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype., Am. J. Respir. Cell Mol. Biol.
    Perrino et al., 2005, Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression., J. Am. Coll. Cardiol.
    Udelsman et al., 1994, Adrenergic regulation of adrenal and aortic heat shock protein., Surgery
    Hupfeld et al., 2003, Beta -Arrestin 1 down-regulation after insulin treatment is associated with supersensitization of beta 2 adrenergic receptor Galpha s signaling in 3T3-L1 adipocytes., Proc. Natl. Acad. Sci. U.S.A.
    Steinlechner et al., 1984, Comparison of the effects of beta-adrenergic agents on pineal serotonin N-acetyltransferase activity and melatonin content in two species of hamsters., J. Pineal Res.
    Mendelson et al., 1984, Regulation of aromatase activity of cultured adipose stromal cells by catecholamines and adrenocorticotropin., Mol. Cell. Endocrinol.
    Sasikumar et al., 2000, Effect of abana an ayurvedic formulation, on lipid peroxidation in experimental myocardial infarction in rats., Indian J. Exp. Biol.
    Matsumoto et al., 2005, Sorcin interacts with sarcoplasmic reticulum Ca(2+)-ATPase and modulates excitation-contraction coupling in the heart., Basic Res. Cardiol.
  • ISOPROTERENOL   LIPE

    Interaction Score: 4.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11160373


    Sources:
    NCI

  • ISOPROTERENOL   AANAT

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6152777


    Sources:
    NCI

  • ISOPROTERENOL   SRI

    Interaction Score: 1.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15754088


    Sources:
    NCI

  • ISOPROTERENOL   IL12B

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ISOPROTERENOL   ADRB2

    Interaction Score: 0.33

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11586955 14734046 11358333 10784181 19464886 16680159 10722 14656380 15105445 11752352 15151902 14752060 12963495


    Sources:
    DTC TdgClinicalTrial NCI TEND PharmGKB TTD

  • ISOPROTERENOL   CP

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12557918


    Sources:
    NCI

  • ISOPROTERENOL   ADRB1

    Interaction Score: 0.27

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    10722 11752352 15908512 16038799 14734046 27643874


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • ISOPROTERENOL   NRG1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14732742


    Sources:
    NCI

  • ISOPROTERENOL   GFAP

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8381971


    Sources:
    NCI

  • ISOPROTERENOL   MAPK10

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12509508


    Sources:
    NCI

  • ISOPROTERENOL   HSPA4

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8047983


    Sources:
    NCI

  • ISOPROTERENOL   CYP19A1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6205918


    Sources:
    NCI

  • ISOPROTERENOL   CSF2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9730867


    Sources:
    NCI

  • ISOPROTERENOL   ADRA1D

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ISOPROTERENOL   PIK3CG

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15936620


    Sources:
    NCI

  • ISOPROTERENOL   ADRA2B

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ISOPROTERENOL   ADRA1B

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ISOPROTERENOL   ADRA2C

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ISOPROTERENOL   ADRA2A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ISOPROTERENOL   ADRA1A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ISOPROTERENOL   TSHR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ISOPROTERENOL   MTOR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ISOPROTERENOL   HIF1A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ISOPROTERENOL   CBX1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ISOPROTERENOL   KDM4E

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ISOPROTERENOL   VDR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ISOPROTERENOL   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ISOPROTERENOL   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: ISOPROTERENOL

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Year of Approval approved before 1982
    Drug Class cardiotonic agents
    Drug Class bronchodilator agents

    Publications:

  • TdgClinicalTrial: ISOPROTERENOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Bronchodilator Agents
    Drug Indications Cardiotonic Agents
    Drug Class small molecule

    Publications:

  • NCI: ISOPROTERENOL

    • Version: 14-September-2017

    Alternate Names:
    C29133 NCI drug code

    Drug Info:

    Publications:
    Lemmens et al., 2004, Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase., Circulation
    Morimoto et al., 2001, Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells., J. Lipid Res.
    Perrino et al., 2005, Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression., J. Am. Coll. Cardiol.

  • DTC: ISOPROTERENOL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL434 ChEMBL Drug ID

    Drug Info:

    Publications:
    Skoumbourdis AP et al., 2009, Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors., Bioorg Med Chem Lett
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol

  • PharmGKB: isoproterenol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    McCrink KA et al., 2016, β<sub>1</sub>-adrenoceptor Arg389Gly polymorphism confers differential β-arrestin-binding tropism in cardiac myocytes., Pharmacogenomics
    Dishy V et al., 2001, The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization., N Engl J Med

  • DTC: ISOPRENALINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1160723 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Isoproterenol

    • Version: 2020.06.01

    Alternate Names:
    D0I8FI TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL434

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21